Skip to content
Trial Eligibility
Menu

Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis

NCT07565103

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

This is a seamless Phase I/II, randomized, double-masked, placebo-controlled, multicenter trial to evaluate single and multiple-dose safety and tolerability of SUM-191 in healthy participants in Parts 1 (SAD) and 2 (MAD) ; and multiple-dose efficacy and safety of SUM-191 in participants with bacterial conjunctivitis in Part 3.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Bacterial Conjunctivitis

Eligibility basics and study details

Study type
Interventional
Phase
Phase 1/2
Ages
18 years and older
Sex
All
Healthy volunteers
Accepted
Sponsor
Senju USA, Inc.
Last updated on ClinicalTrials.gov
November 18, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Florida · 1

  • Segal Drug Trials Inc · Delray Beach, FL

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.